Click on date to see a list of scheduled presentations; click on a therapeutic area to go directly to those presentations.

Table of Contents

### Saturday, December 11
- Multiple Myeloma
- Lymphoma
- Leukemia
- β Thalassemia
- Myelofibrosis
- Myelodysplastic Syndromes
- Other

### Sunday, December 12
- Multiple Myeloma
- Lymphoma
- Leukemia
- β Thalassemia
- Myelofibrosis

### Monday, December 13
- Lymphoma
- Leukemia
- β Thalassemia
- Myelofibrosis
- Myelodysplastic Syndromes
- Other
# Saturday, December 11

## MULTIPLE MYELOMA

### Oral Presentations

**Presentation #117**: Real-world treatment patterns and clinical, economic, and humanistic burden in triple class refractory multiple myeloma: analysis of the CONNECT multiple myeloma (MM) disease registry  
**Lead Author and Presenter**: Derek Tang, Sundar Jagannath*; Bristol Myers Squibb, Princeton, NJ, USA  
**Session**: Outcomes research–lymphoid malignancies: multiple myeloma and other plasma cell disorders

**Presentation #162**: Iberdomide (IBER) in combination with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): results from the dose-expansion phase of the CC-220-MM-001 trial  
**Lead Author and Presenter**: Sagar Lonial, Emory University, Atlanta, GA, USA  
**Session**: Myeloma and plasma cell dyscrasias: clinical-prospective therapeutic trials: novel targets and amyloid

### Poster Presentations

**Presentation #1613**: Pre-clinical and clinical immunomodulatory effects of pomalidomide or CC-92480 in combination with bortezomib in multiple myeloma  
**Lead Author and Presenter**: Chad Bjorklund, Bristol Myers Squibb, Princeton, NJ, USA  
**Session**: Multiple myeloma and plasma cell dyscrasias: basic and translational: poster I

**Presentation #1662**: Impact of elotuzumab plus pomalidomide/dexamethasone on health-related quality of life for patients with relapsed/refractory multiple myeloma (RRMM): final data from the phase 2 ELOQUENT-3 trial  
**Lead Author and Presenter**: Katja Weisel, University Medical Center of Hamburg-Eppendorf, Hamburg, Germany  
**Session**: Myeloma and plasma cell dyscrasias: clinical-prospective therapeutic trials: poster I

**Presentation #1739**: Baseline correlates of complete response to idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy in patients with relapsed and refractory multiple myeloma: subanalysis of the KarMMa trial  
**Lead Author and Presenter**: Nina Shah, University of California San Francisco, San Francisco, CA, USA  
**Session**: Cellular immunotherapies: clinical: poster I

*Presenter differs from lead author*
## Poster Presentations

**Presentation #1978:** Matching-adjusted indirect comparisons of efficacy outcomes in patients with relapsed and refractory multiple myeloma for idecabtagene vicleucel (KarMMa) versus selinexor plus dexamethasone (STORM part 2) and belantamab mafodotin (DREAMM-2): updated analysis with longer follow-up  
**Lead Author and Presenter:** Paula Rodriguez-Otero, Clínica Universidad de Navarra, Pamplona, Spain  
**Session:** Outcomes research—lymphoid malignancies: poster I

## LYMPHOMA

### Oral Presentation

**Presentation #91:** Lisocabtagene maraleucel (liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, versus standard of care (SOC) with salvage chemotherapy (CT) followed by autologous stem cell transplantation (ASCT) as second-line (2L) treatment in patients (pts) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL): results from the randomized phase 3 TRANSFORM study  
**Lead Author and Presenter:** Manali Kamdar, University of Colorado Cancer Center, Denver, CO, USA  
**Session:** Cellular immunotherapies: cellular therapies for lymphomas  
Accepted for ASH Annual Meeting Press Program

### Poster Presentations

**Presentation #1200:** CC-99282 is a novel cereblon (CRBN) E3 ligase modulator (CELMoD) agent with enhanced tumoricidal activity in preclinical models of lymphoma  
**Lead Author and Presenter:** Soraya Carrancio, Bristol Myers Squibb, Princeton, NJ, USA  
**Session:** Molecular pharmacology and drug resistance: lymphoid neoplasms: poster I

**Presentation #1460:** CONNECT® lymphoma disease registry: a US-based, prospective, observational cohort study  
**Lead Author and Presenter:** Christopher Flowers, The University of Texas MD Anderson Cancer Center, Houston, TX, USA  
**Session:** Aggressive lymphomas: clinical and epidemiological: poster I

**Presentation #1762:** Outreach: results from a phase 2 study of lisocabtagene maraleucel (liso-cel) administered as inpatient (Inpt) or outpatient (Outpt) treatment in the nonuniversity setting in patients (pts) with R/R large B-cell lymphoma (LBCL)  
**Lead Author and Presenter:** John Godwin, Earle A. Chiles Research Institute, Portland, OR, USA  
**Session:** Cellular immunotherapies: clinical: poster I
## LEUKEMIA

### Oral Presentations

**Presentation #277:** Real-world evidence comparing venetoclax plus azacitidine (VEN-AZA) vs. intensive chemotherapy (IC) as induction for patients with acute myeloid leukemia (AML): retrospective analysis of an electronic medical records database in the United States  
**Lead Author and Presenter:** Amer Zeidan, Yale University, New Haven, CT, USA  
**Session:** Outcomes research—myeloid malignancies: real world outcomes

**Presentation #279:** Treatment patterns and survival outcomes of patients with acute myeloid leukemia who achieved remission in the CONNECT myeloid disease registry  
**Lead Author and Presenter:** Gail Roboz, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY, USA  
**Session:** Outcomes research—myeloid malignancies: real world outcomes

### Poster Presentations

**Presentation #1243:** Outcomes for patients with late-stage mutant-IDH2 (mIDH2) relapsed/refractory acute myeloid leukemia (R/R AML) treated with enasidenib vs other lower-intensity therapies in the randomized, phase 3 IDHentify trial  
**Lead Author and Presenter:** Courtney DiNardo, The University of Texas MD Anderson Cancer Center, Houston, TX, USA  
**Session:** Acute myeloid leukemias: commercially available therapies, excluding transplantation and cellular immunotherapies: poster I

**Presentation #1244:** Health-related quality of life (HRQoL) during treatment with enasidenib (ENA) plus azacitidine (AZA) in patients with newly diagnosed mutant IDH2 (mIDH2) acute myeloid leukemia (AML) not eligible for intensive chemotherapy (IC)  
**Lead Author and Presenter:** Courtney DiNardo, The University of Texas MD Anderson Cancer Center, Houston, TX, USA  
**Session:** Acute myeloid leukemias: commercially available therapies, excluding transplantation and cellular immunotherapies: poster I
### β THALASSEMIA

**Poster Presentation**

**Presentation #1955:** Systematic literature review of the indirect costs, humanistic burden, patient or caregiver preference, and qualitative outcomes in beta-thalassemia  
**Lead Author and Presenter:** Yesim Aydinok, Ege University, Izmir, Turkey  
**Session:** Outcomes research—non-malignant conditions: poster I

### MYELOFIBROSIS

**Poster Presentations**

**Presentation #1490:** A phase 3 study of efficacy and safety of luspatercept versus placebo in patients with myeloproliferative neoplasm-associated myelofibrosis on JAK2 inhibitor therapy and requiring red blood cell transfusions  
**Lead Author and Presenter:** Ruben Mesa, UT Health San Antonio Cancer Center, San Antonio, TX, USA  
**Session:** Myeloproliferative syndromes: clinical and epidemiological: poster I

**Presentation #1980:** Clinical outcomes at 3 and 6 months of fedratinib therapy following prior ruxolitinib failure: real-world assessment of spleen, symptoms, and hematologic response  
**Lead Author and Presenter:** John Mascarenhas, Icahn School of Medicine at Mount Sinai, New York, NY, USA  
**Session:** Outcomes research—myeloid malignancies: poster I

### MYELODYSPLASTIC SYNDROMES

**Poster Presentation**

**Presentation #1524:** Analysis of duration of response, exposure-adjusted safety and progression to acute myeloid leukemia (AML) for patients with lower-risk myelodysplastic syndromes (LR-MDS) receiving luspatercept in the MEDALIST study  
**Lead Author and Presenter:** Uwe Platzbecker, University Hospital Leipzig, Leipzig, Germany  
**Session:** Myelodysplastic syndromes—clinical and epidemiological: poster I
Presentation #1951: Discordance between treatment guideline recommendations and real-world practice in a group of large integrated delivery networks for venous thromboembolism (VTE) patients: a closer look at VTE patients with cancer

Lead Author and Presenter: Juzer Lotya, Amol Dhamane*; IQVIA Inc., Dublin, Ireland and Bristol Myers Squibb, Princeton, NJ, USA

Session: Outcomes research—non-malignant conditions: poster I

Sunday, December 12

MULTIPLE MYELOMA

Oral Presentation

Presentation #548: Updated clinical and correlative results from the phase I CRB-402 study of the BCMA-targeted CAR-T cell therapy bb21217 in patients with relapsed and refractory multiple myeloma

Lead Author and Presenter: Noopur Raje, Massachusetts General Hospital, Boston, MA, USA

Session: Cellular immunotherapies: cellular therapies for myeloma

Poster Presentations

Presentation #2658: Super-enhancer driven regulation of CKS1B in multiple myeloma: implications in mediating response to BET inhibitor and CELMoD agent combination

Lead Author and Presenter: Aarif Ahsan, Bristol Myers Squibb, Princeton, NJ, USA

Session: Multiple myeloma and plasma cell dyscrasias: basic and translational: poster II

Presentation #2669: CC-92480 enhances cell-autonomous cytotoxicity through blockade of G2/M transition when combined with bortezomib/dexamethasone in pre-clinical multiple myeloma

Lead Author and Presenter: Chad Bjorklund, Bristol Myers Squibb, Princeton, NJ, USA

Session: Multiple myeloma and plasma cell dyscrasias: basic and translational: poster II

*Presenter differs from lead author
<table>
<thead>
<tr>
<th>Presentation</th>
<th>Title</th>
<th>Lead Author and Presenter</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>#2681</td>
<td>Location of the t(4;14) translocation breakpoint identifies a subset of newly-diagnosed multiple myeloma patients with poor prognosis</td>
<td>Nicholas Stong, Bristol Myers Squibb, Princeton, NJ, USA</td>
<td>Multiple myeloma and plasma cell dyscrasias: basic and translational: poster II</td>
</tr>
<tr>
<td>#2731</td>
<td>CC-92480, a potent, novel cereblon E3 ligase modulator (CELMoD) agent, in combination with dexamethasone (DEX) and bortezomib (BORT) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): preliminary results from the phase 1/2 study CC-92480-MM-002</td>
<td>Paul Richardson, Dana-Farber Cancer Institute, Boston, MA, USA</td>
<td>Myeloma and plasma cell dyscrasias: clinical-prospective therapeutic trials: poster II</td>
</tr>
<tr>
<td>#2743</td>
<td>Subsequent anti-myeloma therapy after idecabtagene vicleucel (Ide-cel, bb2121) treatment in patients with relapsed/refractory multiple myeloma from the KarMMa study</td>
<td>Paula Rodriguez-Otero, Clínica Universidad de Navarra, Pamplona, Spain</td>
<td>Myeloma and plasma cell dyscrasias: clinical-prospective therapeutic trials: poster II</td>
</tr>
<tr>
<td>#2835</td>
<td>Updated health-related quality of life results from the KarMMa clinical study in patients with relapsed and refractory multiple myeloma treated with the B-cell maturation antigen-directed chimeric antigen receptor T cell therapy idecabtagene vicleucel (ide-cel, bb2121)</td>
<td>Michel Delforge, University Hospital Leuven, Leuven, Belgium</td>
<td>Cellular immunotherapies: clinical: poster II</td>
</tr>
<tr>
<td>#3041</td>
<td>Idecabtagene vicleucel (ide-cel, bb2121), a B-cell maturation antigen-directed chimeric antigen receptor T cell therapy: qualitative analyses of post-treatment interviews (months 6–24) for patients with relapsed and refractory multiple myeloma in the KarMMa clinical trial</td>
<td>Nina Shah, University of California San Francisco, San Francisco, CA, USA</td>
<td>Outcomes research—lymphoid malignancies: poster II</td>
</tr>
<tr>
<td>Presentation #2271:</td>
<td>Discovery and preclinical characterization of CC 95251, an anti-Sirpa antibody that enhances macrophage-mediated phagocytosis of non-Hodgkin lymphoma (NHL) cells when combined with rituximab</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------------------</td>
<td>--------------------------------------------------------------------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lead Author and Presenter:</td>
<td>Henry Chan, Bristol Myers Squibb, Princeton, NJ, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Session:</td>
<td>Molecular pharmacology and drug resistance: lymphoid neoplasms: poster II</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Presentation #2454:</th>
<th>Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine (AN+AD) for advanced stage classic Hodgkin lymphoma: preliminary safety results from the single-arm phase 2 study (SGN35-027 part B)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lead Author and Presenter:</td>
<td>Hun Ju Lee, The University of Texas MD Anderson Cancer Center, Houston, TX, USA</td>
</tr>
<tr>
<td>Session:</td>
<td>Hodgkin lymphomas and T/NK cell lymphomas: clinical and epidemiological: poster II</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Presentation #2493:</th>
<th>Interim results from the first clinical study of CC-95251, an anti-signal regulatory protein-alpha (SIRPα) antibody, in combination with rituximab in patients with relapsed and/or refractory non-Hodgkin lymphoma (R/R NHL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lead Author and Presenter:</td>
<td>Paolo Strati, The University of Texas MD Anderson Cancer Center, Houston, TX, USA</td>
</tr>
<tr>
<td>Session:</td>
<td>Aggressive lymphomas: prospective therapeutic trials: poster II</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Presentation #2840:</th>
<th>Two-year follow-up of TRANSCEND NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) in relapsed or refractory (R/R) large B-cell lymphomas (LBCL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lead Author and Presenter:</td>
<td>Jeremy Abramson, Massachusetts General Hospital Cancer Center, Boston, MA, USA</td>
</tr>
<tr>
<td>Session:</td>
<td>Cellular immunotherapies: clinical: poster II</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Presentation #3003:</th>
<th>Cost-effectiveness of lisocabtagene maraleucel (liso-cel) versus axicabtagene ciloleucel (axi-cel) for treatment of relapsed or refractory (R/R) large B-cell lymphoma (LBCL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lead Author and Presenter:</td>
<td>Christopher Parker, Bristol Myers Squibb, Uxbridge, United Kingdom</td>
</tr>
<tr>
<td>Session:</td>
<td>Health services research—lymphoid malignancies: poster II</td>
</tr>
</tbody>
</table>
# LEUKEMIA

## Poster Presentations

**Presentation #2314:** OMNIVERSE: a phase 1b study of oral azacitidine plus venetoclax in patients with relapsed/refractory (R/R) or newly diagnosed (ND) acute myeloid leukemia (AML)

**Lead Author and Presenter:** Farhad Ravandi, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

**Session:** Acute myeloid leukemias: commercially available therapies, excluding transplantation and cellular immunotherapies: poster II

**Presentation #3015:** Matching adjusted indirect comparison (MAIC) of oral azacitidine (AZA) versus injectable AZA in patients (pts) with acute myeloid leukemia (AML) in first remission after intensive induction chemotherapy

**Lead Author and Presenter:** Clara Chen, Bristol Myers Squibb, Princeton, NJ, USA

**Session:** Health services research—myeloid malignancies: poster II

## β THALASSEMIA

## Poster Presentation

**Presentation #2984:** Modeling the future blood requirements in patients with transfusion-dependent β-thalassemia in Greece

**Lead Author and Presenter:** Kyriakos Souliotis, Maria Tsironi*; University of Peloponnese, Tripoli, Greece

**Session:** Health services research—non-malignant conditions: poster II

## MYELOFIBROSIS

## Oral Presentation

**Presentation #389:** Safety and tolerability of fedratinib (FEDR), an oral inhibitor of Janus kinase 2 (JAK2), in patients with intermediate- or high-risk myelofibrosis (MF) previously treated with ruxolitinib (RUX): results from the phase 3b FREEDOM trial

**Lead Author and Presenter:** Vikas Gupta, Princess Margaret Cancer Centre, Toronto, ON, Canada

**Session:** Myeloproliferative syndromes: clinical and epidemiological: novel therapies for MPNs and JAK inhibitors for myelofibrosis

*Presenter differs from lead author*
Poster Presentations

**Presentation #2576:** Spleen and symptom responses with fedratinib (FEDR) in patients with myelofibrosis (MF) and substantial splenomegaly

**Lead Author and Presenter:** Jean-Jacques Kiladjian, Hôpital Saint-Louis; Université de Paris, INSERM, Paris, France

**Session:** Myeloproliferative syndromes: clinical and epidemiological: poster II

**Presentation #3059:** Real-world utilization of fedratinib for myelofibrosis post-ruxolitinib: patient characteristics, treatment patterns, and characterization of ruxolitinib failure

**Lead Author and Presenter:** Claire Harrison, Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom

**Session:** Outcomes research—myeloid malignancies: poster II

Monday, December 13

**LYMPHOMA**

Oral Presentation

**Presentation #812:** Completed induction phase analysis of MAGNIFY: phase 3b study of lenalidomide + rituximab (R2) followed by maintenance in relapsed/refractory indolent non-Hodgkin lymphoma

**Lead Author and Presenter:** Frederick Lansigan, Dartmouth–Hitchcock Medical Center, Lebanon, NH, USA

**Session:** Mantle cell, follicular, and other B-cell lymphomas: clinical and epidemiological: follicular lymphoma: advances in treatment approaches

Poster Presentations

**Presentation #3574:** Clinical activity of CC-99282, a novel, oral small molecule cereblon E3 ligase modulator (CELMoD) agent, in patients (pts) with relapsed or refractory non-Hodgkin lymphoma (R/R NHL) – first results from a phase 1, open-label study

**Lead Author and Presenter:** Jean-Marie Michot, Département d’Innovation Thérapeutique et d’Essais Précoces (DITEP), Gustave Roussy Institute of Cancer, Villejuif, France

**Session:** Aggressive lymphomas: prospective therapeutic trials: poster III
### Poster Presentations

**Presentation #3834:** Characteristics of post-infusion chimeric antigen receptor (CAR) T cells and endogenous T cells associated with early and long-term response in lisocabtagene maraleucel (liso-cel)—treated relapsed or refractory (R/R) large B-cell lymphoma (LBCL)

**Lead Author and Presenter:** Jerill Thorpe, Bristol Myers Squibb, Princeton, NJ, USA

**Session:** Cellular immunotherapies: clinical: poster III

**Presentation #3845:** Improved quality of life (QOL) with lisocabtagene maraleucel (liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, compared with standard of care (SOC) as second-line (2L) treatment in patients (pts) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL): results from the phase 3 TRANSFORM study

**Lead Author and Presenter:** Jeremy Abramson, Massachusetts General Hospital Cancer Center, Boston, MA, USA

**Session:** Cellular immunotherapies: clinical: poster III

**Presentation #4098:** Interviews of patients (pts) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) enrolled in 2 lisocabtagene maraleucel (liso-cel) trials on their treatment experience for 3 months after infusion

**Lead Author and Presenter:** Tanya Siddiqi, City of Hope National Medical Center, Duarte, CA, USA

**Session:** Outcomes research—lymphoid malignancies: poster III

### LEUKEMIA

### Oral Presentations

**Presentation #804:** Prognostic impact of NPM1 and FLT3 mutations at diagnosis and presence of measurable residual disease (MRD) after intensive chemotherapy (IC) for patients with acute myeloid leukemia (AML) in remission: outcomes from the Quazar AML-001 trial of oral azacitidine (oral-AZA) maintenance

**Lead Author and Presenter:** Hartmut Döhner, Ulm University Hospital, Ulm, Germany

**Session:** Acute myeloid leukemias: biomarkers, molecular markers and minimal residual disease in diagnosis and prognosis: new options of risk assessment and prediction of therapy response in AML

**Presentation #871:** Long-term overall survival (OS) with oral azacitidine (oral-AZA) in patients with acute myeloid leukemia (AML) in first remission after intensive chemotherapy (IC): updated results from the phase 3 Quazar AML-001 trial

**Lead Author and Presenter:** Andrew H. Wei, The Alfred Hospital, Melbourne, Australia

**Session:** Acute myeloid leukemias: commercially available therapies, excluding transplantation and cellular immunotherapies: updates in treatment for high-risk AML
<table>
<thead>
<tr>
<th>Presentation #3330:</th>
<th>Synergistic combination activity of the novel GSPT1 degrader CC-90009 in acute myeloid leukemia models</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lead Author and Presenter:</td>
<td>Daniel Pierce, Bristol Myers Squibb, Princeton, NJ, USA</td>
</tr>
<tr>
<td>Session:</td>
<td>Molecular pharmacology and drug resistance: myeloid neoplasms: poster III</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Presentation #3355:</th>
<th>Low exposure extended dosing mimicking clinical exposures of the oral formulation of azacitidine results in a sustained hypomethylation and targets leukemic stem cells</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lead Author and Presenter:</td>
<td>Danny Jeyaraju, Bristol Myers Squibb, Princeton, NJ, USA</td>
</tr>
<tr>
<td>Session:</td>
<td>Molecular pharmacology and drug resistance: myeloid neoplasms: poster III</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Presentation #3607:</th>
<th>Dasatinib treatment patterns after pleural effusion among patients diagnosed with chronic myeloid leukemia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lead Author and Presenter:</td>
<td>John Brokars, Bristol Myers Squibb, Princeton, NJ, USA</td>
</tr>
<tr>
<td>Session:</td>
<td>Chronic myeloid leukemia: clinical and epidemiological: poster III</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Presentation #4039:</th>
<th>Healthcare resource utilization and costs in US patients with newly diagnosed acute myeloid leukemia treated with intensive induction chemotherapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lead Author and Presenter:</td>
<td>David Huggar, Thomas W. LeBlanc*; Bristol Myers Squibb, Princeton, NJ, USA and Duke University School of Medicine, Durham, NC, USA</td>
</tr>
<tr>
<td>Session:</td>
<td>Health services research—myeloid malignancies: poster III</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Lead Author and Presenter:</td>
<td>Clara Chen, Bristol Myers Squibb, Princeton, NJ, USA</td>
</tr>
<tr>
<td>Session:</td>
<td>Outcomes research—myeloid malignancies: poster III</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Presentation #4140:</th>
<th>Impact of post-remission maintenance therapy (MT) on outcomes in patients (pts) with newly diagnosed acute myeloid leukemia (AML) in real-world practice</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lead Author and Presenter:</td>
<td>Ravi Potluri, SmartAnalyst Inc., New York, NY, USA</td>
</tr>
<tr>
<td>Session:</td>
<td>Outcomes research—myeloid malignancies: poster III</td>
</tr>
</tbody>
</table>

*Presenter differs from lead author
### β Thalassemia

**Oral Presentation**

**Presentation #761**: Luspatercept redistributes body iron to the liver in transfusion-dependent-thalassemia (TDT) during erythropoietic response  
**Lead Author and Presenter**: Maciej Garbowski, University College London Hospitals, London, United Kingdom  
**Session**: Iron homeostasis and biology: disorders of iron and heme and novel treatments

**Poster Presentations**

**Presentation #3081**: Luspatercept improves quality of life and reduces red blood cell transfusion burden in patients with non-transfusion-dependent β thalassemia in the BEYOND trial  
**Lead Author and Presenter**: Antonis Kattamis, National and Kapodistrian University of Athens, Athens, Greece  
**Session**: Thalassemia and globin gene regulation: poster III

**Presentation #4062**: Understanding the association between red blood cell transfusion dependency and humanistic, psychosocial, and psychological burden in patients with β-thalassemia from the patients’ perspective  
**Lead Author and Presenter**: Kwanza Price, Bristol Myers Squibb, Princeton, NJ, USA  
**Session**: Outcomes research—non-malignant conditions: poster III

### Myelofibrosis

**Poster Presentations**

**Presentation #3643**: A randomized, phase 3 trial of fedratinib versus best available therapy in patients with intermediate-2 or high-risk myelofibrosis previously treated with ruxolitinib (FREEDOM2)  
**Lead Author and Presenter**: Nicola Vianelli, Francesco Passamonti; Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy and University of Insubria and ASST Sette Laghi, Verese, Italy  
**Session**: Myeloproliferative syndromes: clinical and epidemiological: poster III

**Presentation #3645**: Real-world outcomes with fedratinib therapy in patients who discontinued ruxolitinib for primary myelofibrosis  
**Lead Author and Presenter**: Francesco Passamonti, University of Insubria and ASST Sette Laghi, Varese, Italy  
**Session**: Myeloproliferative syndromes: clinical and epidemiological: poster III

*Presenter differs from lead author*
### MYELODYSPLASTIC SYNDROMES

**Poster Presentation**

**Presentation #3686:** Treatment patterns and outcomes of patients with lower-risk myelodysplastic syndromes in the CONNECT myeloid disease registry  
**Lead Author and Presenter:** Rami S. Komrokji, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA  
**Session:** Myelodysplastic syndromes—clinical and epidemiological: poster III

### OTHER

**Oral Presentation**

**Presentation #670:** Anticoagulant treatment patterns and outcomes in patients with venous thromboembolism and active cancer – a nationwide cohort study in France  
**Lead Author and Presenter:** Laurent Bertoletti, CHU de St-Etienne, Université Jean-Monnet, St-Etienne, France  
**Session:** Anticoagulation and antithrombotic therapies

**Poster Presentation**

**Presentation #3912:** Improved overall survival of patients treated with abatacept in combination with a calcineurin inhibitor and methotrexate following 7/8 HLA-matched unrelated allogeneic hematopoietic stem cell transplantation: analysis of the Center for International Blood and Marrow Transplant Research database  
**Lead Author and Presenter:** Leslie Kean, Dana-Farber Cancer Institute, Boston, MA, USA  
**Session:** Allogeneic transplantation: acute and chronic GVHD, immune reconstitution: poster III